Skip to content
ESPT
MARKETS / NASDAQ / Health care / Pharmaceuticals / PBYI
NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

Puma Biotechnology, Inc. PBYI

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$228.4M
▼ 0.9% YoY
$31.1M
▲ 2.8% YoY
$41.7M
▲ 7.4% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Puma Biotechnology, Inc. develops and commercializes products for cancer care and treatment. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. It has in-licensed, and is responsible for the global development and commercialization of, alisertib, a selective, small-molecule inhibitor of Aurora Kinase A. In the United States, it sells its products through a specialty pharmacy network consisting of Accredo, CVS, ONCO 360, Optum and Biologics, and a specialty distributor network consisting of McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care. As of December 31, 2025, its workforce consisted of 179 full-time employees. It was originally incorporated in the State of Delaware in April 2007 under the name Innovative Acquisitions Corp. In October 2011, it acquired Puma Biotechnology, Inc., a privately held Delaware corporation formed on September 15, 2010, which became its wholly owned subsidiary, subsequently merged with and into it, and it changed its name to Puma Biotechnology, Inc.

Written from the business description in PUMA BIOTECHNOLOGY, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 228.4M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 228.4 · Net income 31.1
100M200M-150M-300M
201120142017202020232025
Compound annual growth
+0.0%
+0.3%
+2396.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +0.3% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

14 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 16.3% · Net 13.6%
-500%-1000%
201120182025
ROE
FY2025 · ROE 28.0%
20%40%-100%-200%
201120182025
Three returns, three denominators.
Gross margin74.5%
Operating margin16.3%
Net margin13.6%
EBITDAUSD 37.7M

Each USD of equity produced 28 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 41.7
15M30M-100M-200M
201120182025
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 216.3M
EquityUSD 130.3M
CashUSD 29.6M
Gross debtUSD 22.5M
Net debtUSD -7.1M
Current ratio2.00×

The company holds more cash than debt.

The 15-year record

15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
PBYI, 15-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B0.20.20.20.20.30.20.30.30.0◌◌◌◌◌◌
Operating income $B0.00.00.00.00.0−0.0−0.0−0.1−0.3−0.3−0.2−0.1−0.1−0.1−0.0
EBITDA $B0.00.00.00.00.0−0.0−0.0−0.1−0.3◌◌◌◌◌◌
Income tax $B0.0−0.00.00.00.00.00.00.00.00.00.00.00.00.0◌
Net income $B0.00.00.00.0−0.0−0.1−0.1−0.1−0.3−0.3−0.2−0.1−0.1−0.1−0.0
Free cash flow $B0.00.00.0−0.00.00.00.0−0.0−0.2−0.1−0.2−0.1−0.1◌−0.0
EPS, diluted $0.610.620.450.00−0.72−1.52−1.95−2.99−7.85−8.29−7.45−4.73−1.90−3.42−1.32
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————
ROE %28.041.657.5———−292.0−259.3−221.9−132.8−148.1−141.2−51.3−81.1−18.8
Shares out B0.050.050.050.050.040.040.040.040.040.040.030.030.030.030.02

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 1 failure in 60 reconciliationsAUDITED

Reconciled in 14 of the 15 fiscal years we could check. 10 checks were skipped: revenue is not tagged before 2017. Eight checks were skipped: the balance sheet is not tagged before 2011. Four checks were skipped: EPS is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency1 failure
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image